Cytokinetics
CYTK
211 hedge funds and large institutions have $3.11B invested in Cytokinetics in 2021 Q3 according to their latest regulatory filings, with 48 funds opening new positions, 97 increasing their positions, 45 reducing their positions, and 25 closing their positions.
193% more call options, than puts
Call options by funds: $16.7M | Put options by funds: $5.69M
116% more repeat investments, than reductions
Existing positions increased: 97 | Existing positions reduced: 45
115% more capital invested
Capital invested by funds: $1.45B → $3.11B (+$1.67B)
92% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 25
60% more funds holding in top 10
Funds holding in top 10: 5 → 8 (+3)
11% more funds holding
Funds holding: 190 → 211 (+21)
2.7% more ownership
Funds ownership: 105.38% → 108.08% (+2.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$118M |
| 2 |
BlackRock
New York
|
+$47.4M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$43.4M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$29.4M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$29.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MWNA
Marshall Wace North America
New York
|
-$32.4M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$14.1M |
| 3 |
VC
Vivo Capital
Palo Alto,
California
|
-$13.9M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
-$11.8M |
| 5 |
IHAM
Integral Health Asset Management
New York
|
-$11M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
FRM
226
Fox Run Management
Greenwich,
Connecticut
| – | -$336K | -16,978 | Closed |
|
|
DTL
227
Dynamic Technology Lab
Singapore
| – | -$331K | -16,749 | Closed |
|
|
HF
228
HRT Financial
New York
| – | -$247K | -12,500 | Closed |
|
|
BFM
229
Boothbay Fund Management
New York
| – | -$242K | -12,217 | Closed |
|
|
PCM
230
Pinz Capital Management
New York
| – | -$20K | -1,000 | Closed |
|
|
CG
231
Cutler Group
San Francisco,
California
| – | -$14.4K | -489 | -98% |
|
|
GRP
232
Global Retirement Partners
San Rafael,
California
| – | -$6K | -300 | Closed |
|
|
ASN
233
Advisory Services Network
Atlanta,
Georgia
| – | -$3K | -150 | Closed |
|
|
AWM
234
Avior Wealth Management
Omaha,
Nebraska
| – | -$1K | -100 | Closed |
|
235
Rockefeller Capital Management
New York
| – | -$1K | -100 | Closed |
|
|
EVM
236
Eaton Vance Management
Boston,
Massachusetts
| – | +$3.3K | +112 | +7% |
|
CYTK Hedge Fund Activity: Q3 2021 in Review
211 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Cytokinetics (CYTK) for Q3 2021, worth a combined $3.11B — up 115% from $1.45B a quarter earlier.
Buyers outnumbered sellers: 48 funds opened new CYTK positions and 25 closed out — a net gain of 23 holders — while 97 added to existing stakes and 45 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $118M. The largest seller was Marshall Wace North America, cutting an estimated $32.4M.
- 211 institutional investors held Cytokinetics (CYTK) as of Q3 2021, up from 190 in Q2 2021.
- Funds reported $3.11B of Cytokinetics stock for Q3 2021, up 115% quarter-over-quarter.
- 48 funds opened new Cytokinetics positions in Q3 2021 and 25 closed out, a net change of +23 holders.
- The largest Cytokinetics buyer in Q3 2021 was Fidelity Investments, an estimated $118M added.
- The largest Cytokinetics seller in Q3 2021 was Marshall Wace North America, an estimated $32.4M sold.
Based on aggregated 13F filings for Q3 2021.